We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
RESP-X continues to exhibit strong safety and tolerability profile
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate
Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new “Netflix” style subscription model for antibiotic reimbursement,…
Latest News
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
RESP-X continues to exhibit strong safety and tolerability profile
Clinical candidate nominated for COV-X programme
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate
Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
Accelerates plans for Phase IIa study
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
This designation gives MET-X an accelerated U.S. regulatory pathway and an additional…
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a…
CARB-X Receives Additional $370m from U.S. Government and Wellcome
Enables continued investment in innovative projects to tackle the growing global threat…
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022